ArticleScientific reports2025
Effects of peptides derived from active sites of visfatin on wound healing.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Natural Extracts in Skin Repair and Wound Healing: Phytochemical Mechanisms and Dermopharmaceutical Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Multidimensional Regulatory Mechanisms and Targeted Therapeutic Strategies for Inhibited Keratinocyte Proliferation in Diabetic Wounds.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Severe wounds (e.g., burns) often result in irreversible scarring, leading to cosmetic and functional impairments as well as secondary complications such as reduced skin strength and itching. In the case of chronic wounds and diabetic ulcers, impaired healing capacity is the primary clinical concern, not scarring. These wounds frequently fail to heal, presenting a therapeutic challenge. Despite ongoing research, the development of scarless, cost-effective, and clinically viable therapies for these complex wounds remains a significant challenge. Angiogenesis plays a crucial role in skin wound healing. Visfatin has been known to have angiogenic and wound healing effects. In our previous study, we derived two angiogenic peptides (Vis-1 and Vis-2) from the active site of visfatin. Therefore, this study is aimed to investigate the wound healing potential of these two peptides using a scratch assay system (in vitro) and full-thickness excision wound healing mice (in vivo). Only Vis-1 peptide had a significant wound healing effect in the in vitro assay by promoting proliferation and migration of keratinocytes and dermal fibroblasts, possibly through activation of Wnt/β-Catenin and MAPK signaling pathway. Vis-1 peptide also showed remarkable wound healing effects in the in vivo assay by accelerating wound healing, inducing angiogenesis, promoting neo-epithelium, decreasing granulation tissue, and increasing collagen fiber formation. These results suggest that the Vis-1 peptide has a potent wound healing activity and may contribute as a novel wound healing agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.